有5月世界肺癌大会的最新信息吗?

七夕雨

<p>天津肿瘤做的吧！看来不错，希望病情一直稳定，坚持！价格应该不低吧！可以介绍一下这个的费用吗？</p>

jimmy112199

目前已知如下：<br/><br/>1)顺铂/诺维本 + 爱比妥 和无爱比妥的3期试药结果。<br/>2)顺铂/依立替康 与 铂/<font size="-1">依托泊甙 比较(小细胞癌)<br/>3)一线化疗后用力比泰的维持治疗。<br/>4)CP-517，871治疗NASLC<br/>5)</font><font size="-1">索拉非尼停止</font>试药<br/>6)分子标记预测相关<font size="-1">化疗有效性。<br/>7)卡</font>铂/<font size="-1">力比泰</font>与 <font size="-1">卡</font>铂/<font size="-1">依托泊甙 比较(小细胞癌)<br/>8)TARCEVA对</font> EGFR变异NSCLC研究。<br/>9)<font size="-1">卡</font>铂/<font size="-1">力比泰</font> + 爱比妥 和无爱比妥同时胸部放疗比较结果。<br/>10)恶性胸腔积液的<font size="-1">小细胞癌有限的还是延伸的。</font>

jimmy112199

本次大会提交论文目录，共 200多篇(1)<br/><br/><table width="98%" cellspacing="0" cellpadding="3" border="0"><tbody><tr><td colspan="2"><h1>Metastatic Lung Cancer</h1></td></tr><tr><td width="1%" valign="top"><h3>Category:</h3></td><td width="99%"><h4>Lung Cancer--Metastatic Lung Cancer</h4></td></tr><tr><td width="1%" valign="top"><h3>Meeting:</h3></td><td width="99%"><h4><a href="http://www.abstract.asco.org/ConfCatView_55.html">2008 ASCO Annual Meeting</a></h4></td></tr><tr><td width="1%" valign="bottom"><h3>Sort by:</h3></td><td width="99%" valign="top"><h4><input type="radio"/> title<input type="radio" checked="checked"/> abstract no.<input type="radio"/> first author</h4></td></tr><tr><td colspan="2"><table width="98%" cellspacing="0" cellpadding="3" border="0"><tbody><tr><td width="98%" valign="top" id="vmtableheader">Abstract Title</td><td width="1%" valign="top" nowrap="nowrap" id="vmtableheader">First Author &#160; &#160;</td><td width="1%" valign="top" nowrap="nowrap" id="vmtableheader">Abstract No.</td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30338.html">FLEX:<br/>A randomized, multicenter, phase III study of cetuximab in combination<br/>with cisplatin/vinorelbine (CV) versus CV alone in the first-line<br/>treatment of patients with advanced non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>R. Pirker </h4></td><td width="1%" valign="top"><h4>3</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35772.html">S0124:<br/>A randomized phase III trial comparing irinotecan/cisplatin (IP) with<br/>etoposide/cisplatin (EP) in patients (pts) with previously untreated<br/>extensive stage small cell lung cancer (E-SCLC).</a></td><td width="1%" valign="top"><h4>R. B. Natale </h4></td><td width="1%" valign="top"><h4>7512</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30840.html">Topotecan/cisplatin<br/>(TP) compared to cisplatin/etoposide (PE) for patients with extensive<br/>disease-small cell lung cancer (ED- SCLC): Final results of a<br/>randomised phase III trial.</a></td><td width="1%" valign="top"><h4>D. F. Heigener </h4></td><td width="1%" valign="top"><h4>7513</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33330.html">Characterization of NSCLC patients responding to anti-IGF-IR therapy.</a></td><td width="1%" valign="top"><h4>A. Gualberto </h4></td><td width="1%" valign="top"><h4>8000</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34724.html">Molecular<br/>and clinical subgroup analyses from a phase III trial comparing<br/>gefitinib with docetaxel in previously treated non-small cell lung<br/>cancer (INTEREST).</a></td><td width="1%" valign="top"><h4>J. Douillard </h4></td><td width="1%" valign="top"><h4>8001^</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30948.html">Reproducibility of computed tomography (CT) measurements of lung cancer.</a></td><td width="1%" valign="top"><h4>L. P. James </h4></td><td width="1%" valign="top"><h4>8002</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34452.html">ilot<br/>study of early repeated 18F-FDG PET during cycle 1 to predict objective<br/>response to chemotherapy in advanced non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>U. Ricardi </h4></td><td width="1%" valign="top"><h4>8003</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31283.html">Epidemiology<br/>study of never-smokers with non-small cell lung cancer (NSCLC): High<br/>percentages of Asian and Hispanic female never-smokers and the<br/>significance of Asian ethnicity.</a></td><td width="1%" valign="top"><h4>S. I. Ou </h4></td><td width="1%" valign="top"><h4>8004</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30340.html">ack<br/>years of cigarette smoking as a predictor of survival in 2,013 patients<br/>with stage IIIb/IV non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>Y. Y. Janjigian </h4></td><td width="1%" valign="top"><h4>8005</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32331.html">Frequency and distinctive spectrum of <i>KRAS</i> mutations in never smokers with lung adenocarcinoma.</a></td><td width="1%" valign="top"><h4>G. J. Riely </h4></td><td width="1%" valign="top"><h4>8006</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31091.html">Time-course<br/>MALDI-TOF-MS serum peptide profiling of non-small cell lung cancer<br/>patients treated with bortezomib, cisplatin and gemcitabine.</a></td><td width="1%" valign="top"><h4>J. Voortman </h4></td><td width="1%" valign="top"><h4>8007</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32337.html">VeriStrat predicts survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab.</a></td><td width="1%" valign="top"><h4>J. S. Salmon </h4></td><td width="1%" valign="top"><h4>8008</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34350.html">Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC.</a></td><td width="1%" valign="top"><h4>J. V. Heymach </h4></td><td width="1%" valign="top"><h4>8009</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35877.html">Correlation<br/>between plasma cytokine/angiogenic factors (C/AF) and signaling<br/>pathways activation from baseline tumor biopsy specimens in patients<br/>with advanced non small cell lung cancer (NSCLC): Preliminary analysis<br/>from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer<br/>Elimination (BATTLE) Clinical Study.</a></td><td width="1%" valign="top"><h4>H. T. Tran </h4></td><td width="1%" valign="top"><h4>8010</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31696.html">Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study.</a></td><td width="1%" valign="top"><h4>T. E. Ciuleanu </h4></td><td width="1%" valign="top"><h4>8011</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31815.html">Randomized<br/>phase III study of platinum-doublet chemotherapy followed by gefitinib<br/>versus continued platinum-doublet chemotherapy in patients (pts) with<br/>advanced non-small cell lung cancer (NSCLC): Results of West Japan<br/>Thoracic Oncology Group trial (WJTOG.</a></td><td width="1%" valign="top"><h4>T. Hida</h4></td><td width="1%" valign="top"><h4>LBA8012</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30323.html">Duration of chemotherapy for advanced non-small cell lung cancer: An updated systematic review and meta-analysis.</a></td><td width="1%" valign="top"><h4>Y. Soon </h4></td><td width="1%" valign="top"><h4>8013</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31135.html">A<br/>randomized discontinuation phase II study of sorafenib versus placebo<br/>in patients with non-small cell lung cancer who have failed at least<br/>two prior chemotherapy regimens: E2501.</a></td><td width="1%" valign="top"><h4>J. H. Schiller </h4></td><td width="1%" valign="top"><h4>8014</h4></td></tr></tbody></table></td></tr></tbody></table><br/>

[此贴子已经被作者于2008-5-31 15:44:18编辑过]

jimmy112199

本次大会提交论文目录(2)<br/><br/><table width="98%" cellspacing="0" cellpadding="3" border="0"><tbody><tr id="vmtablerowdark"><td width="1%" valign="top"><br/></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33541.html">High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC.</a></td><td width="1%" valign="top"><h4>D. D. Karp </h4></td><td width="1%" valign="top"><h4>8015</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33500.html">Randomized
phase III trial of paclitaxel/carboplatin with or without PF-3512676 as
first line treatment of advanced non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>V. Hirsh </h4></td><td width="1%" valign="top"><h4>8016</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35534.html">Randomized
phase III trial of gemcitabine/cisplatin with or without PF-3512676 as
first line treatment of advanced non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>C. Manegold </h4></td><td width="1%" valign="top"><h4>8017</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34143.html">A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99.</a></td><td width="1%" valign="top"><h4>G. L. Lemma </h4></td><td width="1%" valign="top"><h4>8018</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32835.html">rediction
of survival benefits from progression-free survival in patients with
advanced non small cell lung cancer: Evidence from a pooled analysis of
2,838 patients randomized in 7 trials.</a></td><td width="1%" valign="top"><h4>M. E. Buyse </h4></td><td width="1%" valign="top"><h4>8019</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31650.html">Comparison
of progression-free survival (PFS) with best or confirmed response (BR,
CR) as an endpoint for overall survival (OS) in advanced non small cell
lung cancer (A-NSCLC): A North Central Cancer Treatment Group (NCCTG)
investigation.</a></td><td width="1%" valign="top"><h4>S. J. Mandrekar </h4></td><td width="1%" valign="top"><h4>8021</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32962.html">Role
of time to progression as a surrogate marker for overall survival in
patients with advanced non-small-cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>K. Hotta </h4></td><td width="1%" valign="top"><h4>8022</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32916.html">Randomized
phase IIb trial evaluating the therapeutic vaccine TG4010
(MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced
non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>R. Ramlau </h4></td><td width="1%" valign="top"><h4>8023</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34083.html">hase
III open-label comparison of gemcitabine/oxaliplatin versus
paclitaxel/carboplatin as first line therapy for advanced non-small
cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>C. H. Weissman </h4></td><td width="1%" valign="top"><h4>8024</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34237.html">A
randomized open-label study of gefitinib versus docetaxel in patients
with advanced/metastatic non-small cell lung cancer (NSCLC) who have
previously received platinum-based chemotherapy.</a></td><td width="1%" valign="top"><h4>D. Lee </h4></td><td width="1%" valign="top"><h4>8025</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32355.html">reliminary
activity and safety results from a phase I clinical trial of
PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with
NSCLC.</a></td><td width="1%" valign="top"><h4>. A. Janne </h4></td><td width="1%" valign="top"><h4>8027</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_36019.html">Activity
and tolerance of XL647 in NSCLC patients with acquired resistance to
EGFR-TKIs: Preliminary results of a phase II trial.</a></td><td width="1%" valign="top"><h4>V. A. Miller </h4></td><td width="1%" valign="top"><h4>8028^</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35276.html">Efficacy
and safety of AZD6244 (ARRY-142886) as second/third-line treatment of
patients (pts) with advanced non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>V. Tzekova </h4></td><td width="1%" valign="top"><h4>8029</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35055.html">Randomized
phase II trial of two dosing schedules of BI 2536, a novel Plk-1
inhibitor, in patients with relapsed advanced or metastatic
non-small-cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>J. Von Pawel </h4></td><td width="1%" valign="top"><h4>8030</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35241.html">FAST-ACT:
A phase II randomized double-blind trial of sequential erlotinib and
chemotherapy as first-line treatment in patients (pts) with stage
IIIB/IV non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>J. S. Lee </h4></td><td width="1%" valign="top"><h4>8031</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35773.html">Intermittent
erlotinib (ERL) in combination with pemetrexed (PEM): Phase I schedules
designed to achieve pharmacodynamic separation.</a></td><td width="1%" valign="top"><h4>A. M. Davies </h4></td><td width="1%" valign="top"><h4>8032</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35688.html">redictive
value of RRM1 and ERCC1 protein levels in a prospective community-based
trial of gemcitabine/carboplatin (GC) vs gemcitabine (G) alone.</a></td><td width="1%" valign="top"><h4>G. Bepler </h4></td><td width="1%" valign="top"><h4>8033</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30694.html">Genetic
polymorphisms correlate with overall survival (OS) in advanced
non-small cell lung cancer (NSCLC) treated with carboplatin (CBDCA) and
paclitaxel (PTX).</a></td><td width="1%" valign="top"><h4>N. Yamamoto </h4></td><td width="1%" valign="top"><h4>8034</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33216.html">Impact
of EGFR and KRAS genotype on outcomes in a clinical trial registry of
NSCLC patients initially treated with erlotinib or gefitinib.</a></td><td width="1%" valign="top"><h4>D. M. Jackman </h4></td><td width="1%" valign="top"><h4>8035</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31149.html">Insulin-like
growth factor receptor 1 (IGFR-1) and outcome measures in advanced
non-small cell lung cancer (NSCLC) patients treated with gefitinib.</a></td><td width="1%" valign="top"><h4>M. J. Fidler </h4></td><td width="1%" valign="top"><h4>8036</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31514.html">Spanish
Lung Adenocarcinoma Trial (SLAT) of customized treatment based on EGFR
mutations (mut) and BRCA1 mRNA expression: Ancillary analyses of
Abraxas and RAP80 expression.</a></td><td width="1%" valign="top"><h4>R. Rosell </h4></td><td width="1%" valign="top"><h4>8037</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31581.html">Erlotinib
customization based on epidermal growth factor receptor (EGFR)
mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p).</a></td><td width="1%" valign="top"><h4>R. Porta </h4></td><td width="1%" valign="top"><h4>8038</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31238.html">Sorafenib
in patients with platinum (plat) treated extensive stage small cell
lung cancer (E-SCLC): A SWOG (S0435) phase II trial.</a></td><td width="1%" valign="top"><h4>B. J. Gitlitz </h4></td><td width="1%" valign="top"><h4>8039</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32158.html">A
randomized phase II trial of amrubicin (AMR) vs. topotecan as
second-line treatment in extensive-disease small-cell lung cancer
(SCLC) sensitive to platinum-based first-line chemotherapy.</a></td><td width="1%" valign="top"><h4>R. M. Jotte </h4></td><td width="1%" valign="top"><h4>8040</h4></td></tr></tbody></table><br/>

jimmy112199

<table width="98%" cellspacing="0" cellpadding="3" border="0"><tbody><tr id="vmtablerowdark"><td width="1%" valign="top"><br/></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33149.html">A
phase II trial of single-agent amrubicin (AMR) in patients with
extensive disease small cell lung cancer (ED-SCLC) that is refractory
or progressive within 90 days of completion of first-line
platinum-based chemotherapy.</a></td><td width="1%" valign="top"><h4>D. S. Ettinger </h4></td><td width="1%" valign="top"><h4>8041</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32408.html">Randomized,
phase II trial comparing amrubicin with topotecan in patients (pts)
with previously treated small cell lung cancer (SCLC).</a></td><td width="1%" valign="top"><h4>S. Sugawara </h4></td><td width="1%" valign="top"><h4>8042</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32349.html">Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer.</a></td><td width="1%" valign="top"><h4>W. L. Akerley </h4></td><td width="1%" valign="top"><h4>8043</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33452.html">emetrexed
and carboplatin plus bevacizumab with maintenance pemetrexed and
bevacizumab as first-line therapy for advanced non-squamous non-small
cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>J. D. Patel </h4></td><td width="1%" valign="top"><h4>8044</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33495.html">Two
randomised phase III, double blind, placebo controlled trials of
thalidomide in patients with advanced non-small cell lung cancer
(NSCLC) and small cell lung cancer (SCLC).</a></td><td width="1%" valign="top"><h4>S. Lee </h4></td><td width="1%" valign="top"><h4>8045</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34773.html">MERIT:
Analysis of differential gene expression in patients (pts) with
advanced non-small-cell lung cancer (NSCLC) treated with erlotinib.</a></td><td width="1%" valign="top"><h4>. Delmar </h4></td><td width="1%" valign="top"><h4>8046^</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30827.html">Long-term
survival with gefitinib (ZD 1839) therapy for advanced
bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG)
study S0126.</a></td><td width="1%" valign="top"><h4>H. West </h4></td><td width="1%" valign="top"><h4>8047</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31406.html">Risk
of second lung cancer in patients with previously treated lung cancer:
Analysis of the Surveillance, Epidemiology and End Results (SEER)
registry.</a></td><td width="1%" valign="top"><h4>. Sivakumaran </h4></td><td width="1%" valign="top"><h4>8048</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31866.html">Safety
of first-line bevacizumab-based therapy with concomitant cardiovascular
or anticoagulation medication in advanced or recurrent non-squamous
non-small cell lung cancer (NSCLC) in MO19390 (SAiL).</a></td><td width="1%" valign="top"><h4>F. Griesinger </h4></td><td width="1%" valign="top"><h4>8049</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31040.html">A
randomized phase II study of pemetrexed (P) versus
pemetrexed-carboplatin (PC) as second line treatment for patients (pts)
with advanced non-small-cell lung cancer (NSCLC)- NVALT 7.</a></td><td width="1%" valign="top"><h4>E. F. Smit </h4></td><td width="1%" valign="top"><h4>8050</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32637.html">A
phase 1/2 study investigating the combination of RAD001 (R)
(everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients
(pts) with advanced non-small cell lung cancer (NSCLC) previously
treated with chemotherapy (C): Phase 1 results.</a></td><td width="1%" valign="top"><h4>V. Papadimitrakopoulou </h4></td><td width="1%" valign="top"><h4>8051</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31189.html">Single
agent vs combination chemotherapy (CT) as second-line treatment of
advanced non-small-cell lung cancer (NSCLC): A meta-analysis of
individual data of five randomized trials.</a></td><td width="1%" valign="top"><h4>M. Di Maio </h4></td><td width="1%" valign="top"><h4>8052</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35808.html">Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2.</a></td><td width="1%" valign="top"><h4>N. A. Rizvi </h4></td><td width="1%" valign="top"><h4>8053</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30815.html">The
influence of sex on efficacy, toxicity and delivery of treatment in
National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)
non-small cell lung cancer (NSCLC) chemotherapy trials.</a></td><td width="1%" valign="top"><h4>. Wheatley-Price </h4></td><td width="1%" valign="top"><h4>8054</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34392.html">A
phase II study of erlotinib (E) and bevacizumab (B) in chemo naive
patients (pts) with locally advanced or metastatic non small cell lung
cancer (NSCLC): Predictive value of molecular imaging.</a></td><td width="1%" valign="top"><h4>V. van den Boogaart </h4></td><td width="1%" valign="top"><h4>8055</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33313.html">Acquired
resistance to epidermal growth factor receptor (EGFR) kinase inhibitors
associated with a novel T854A mutation in a patient with EGFR-mutant
lung adenocarcinoma.</a></td><td width="1%" valign="top"><h4>J. Bean </h4></td><td width="1%" valign="top"><h4>8056</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31442.html">Induction
of immune responses and clinical activity in a phase II trial of
IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients.</a></td><td width="1%" valign="top"><h4>M. Barve </h4></td><td width="1%" valign="top"><h4>8057</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34786.html">Effects
of diagnostic method and surgery on safety of first-line bevacizumab
plus chemotherapy in advanced or recurrent non-squamous non-small cell
lung cancer (NSCLC): MO19390 (SAiL).</a></td><td width="1%" valign="top"><h4>C. Tsai </h4></td><td width="1%" valign="top"><h4>8058</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34595.html">Rates of central nervous system progression in non-small cell lung cancer patients treated with EGFR-TKI's vs. chemotherapy.</a></td><td width="1%" valign="top"><h4>M. S. Rabin </h4></td><td width="1%" valign="top"><h4>8059</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34801.html">Tolerability
of pemetrexed versus placebo as a maintenance therapy in advanced
non-small cell lung cancer: Evidence from a large randomized study.</a></td><td width="1%" valign="top"><h4>C. C. Zielinski </h4></td><td width="1%" valign="top"><h4>8060</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34846.html">reliminary
results of a randomized phase II trial of pemetrexed (P) + carboplatin
(Cb) ± enzastaurin (ENZ) versus docetaxel (D) + Cb as first-line
treatment of patients with stage IIIB/IV non-small cell lung cancer
(NSCLC).</a></td><td width="1%" valign="top"><h4>D. M. Kocs </h4></td><td width="1%" valign="top"><h4>8061</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35839.html">redictive
value of EGFR and KRAS mutations detected in plasma from non-small cell
lung cancer (NSCLC) patients treated with docetaxel and intermittent
erlotinib.</a></td><td width="1%" valign="top"><h4>. C. Mack </h4></td><td width="1%" valign="top"><h4>8062</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31481.html">hase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM).</a></td><td width="1%" valign="top"><h4>A. K. Nowak </h4></td><td width="1%" valign="top"><h4>8063</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34689.html">Cisplatin
in non-small cell lung cancer (NSCLC)--Reducing the most prominent
toxicity, emesis: Results of a meta-analysis with 1527 patients in
randomized clinical trials (RCTs) testing the addition of an NK1
antagonist.</a></td><td width="1%" valign="top"><h4>R. J. Gralla </h4></td><td width="1%" valign="top"><h4>8064</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30794.html">Anticoagulation
and bleeding: A pooled analysis of lung cancer trials of the National
Cancer Institute of Canada Clinical Trials Group.</a></td><td width="1%" valign="top"><h4>A. Le Ma&#238;tre </h4></td><td width="1%" valign="top"><h4>8065</h4></td></tr></tbody></table>

jimmy112199

<table width="98%" cellspacing="0" cellpadding="3" border="0"><tbody><tr id="vmtablerowlight"><td width="1%" valign="top"><br/></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32144.html">hase
II trial of pemetrexed (P) and carboplatin (C) in previously untreated
extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study.</a></td><td width="1%" valign="top"><h4>J. R. Jett </h4></td><td width="1%" valign="top"><h4>8066</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35351.html">High
expression of epithelial-mesenchymal transition (EMT) markers in
malignant mesothelioma and possible therapeutic intervention using an
N-cadherin antagonist.</a></td><td width="1%" valign="top"><h4>M. B. Suraokar </h4></td><td width="1%" valign="top"><h4>8067</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31605.html">Effect
of first-line treatment and CHFR and 14-3-3σ methylation status on
survival to second-line chemotherapy or EGFR tyrosine kinase inhibitors
(TKIs) in stage IV non-small-cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>J. Sánchez Sr.</h4></td><td width="1%" valign="top"><h4>8068</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34359.html">Randomized
phase II study of sequential carboplatin/paclitaxel (CP) and gefitinib
(G) in chemotherapy-na&#239;ve patients with advanced non-small-cell lung
cancer (NSCLC): Final results.</a></td><td width="1%" valign="top"><h4>H. Nokihara </h4></td><td width="1%" valign="top"><h4>8069</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31182.html">First-line gefitinib for poor <i>S</i> patients with EGFR mutations.</a></td><td width="1%" valign="top"><h4>K. Kobayashi </h4></td><td width="1%" valign="top"><h4>8070</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31942.html">IFCT0401-bio
phase II trial: Gefitinib administered as 1st-line in non-resectable
adenocarcinoma with bronchioloalveolar carcinoma features
(ADC-BAC)--Predictive biomarkers of efficacy and survival.</a></td><td width="1%" valign="top"><h4>m. Wislez </h4></td><td width="1%" valign="top"><h4>8071</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31916.html">Comparison
of safety and efficacy between squamous and non-squamous non-small cell
lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404).</a></td><td width="1%" valign="top"><h4>M. J. McKeage </h4></td><td width="1%" valign="top"><h4>8072</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34455.html">Detection
of EGFR mutations in samples with few cancer cells in non-small cell
lung cancer (NSCLC) patients (p) and distribution of exon 20 mutations.</a></td><td width="1%" valign="top"><h4>N. Reguart </h4></td><td width="1%" valign="top"><h4>8073</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34195.html">Retrospective
study of clinical and radiographic risk factors associated with early
onset, severe pulmonary hemorrhage in bevacizumab-treated patients with
advanced non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>A. B. Sandler </h4></td><td width="1%" valign="top"><h4>8074</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35559.html">Non-invasive detection of EGFR T790M in gefitinib/erlotinib resistant NSCLC.</a></td><td width="1%" valign="top"><h4>Y. Kuang </h4></td><td width="1%" valign="top"><h4>8075</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30895.html">Baseline
quality of life (QOL) as a prognostic factor for overall survival (OS)
in patients (Pts) with advanced stage non-small cell lung cancer
(A-NSCLC): An analysis of NCCTG studies.</a></td><td width="1%" valign="top"><h4>S. E. Schild </h4></td><td width="1%" valign="top"><h4>8076</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32417.html">reliminary
treatment patterns and safety outcomes for non-small cell lung cancer
(NSCLC) from ARIES, a bevacizumab treatment observational cohort study
(OCS).</a></td><td width="1%" valign="top"><h4>T. J. Lynch </h4></td><td width="1%" valign="top"><h4>8077</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33055.html">Cediranib
(AZD2171) for the treatment of recurrent small cell lung cancer (SCLC):
A California Consortium phase II study (NCI # 7097).</a></td><td width="1%" valign="top"><h4>S. S. Ramalingam </h4></td><td width="1%" valign="top"><h4>8078</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32638.html">Safety
of bevacizumab (Bv) therapy in combination with chemotherapy in
subjects with non-small cell lung cancer (NSCLC) treated on ATLAS.</a></td><td width="1%" valign="top"><h4>J. Polikoff </h4></td><td width="1%" valign="top"><h4>8079</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33284.html">A
phase II second-line study of pemetrexed (pem) in combination with
bevacizumab (bev) in patients with advanced non-small cell lung cancer
(NSCLC): An NCCTG and SWOG study.</a></td><td width="1%" valign="top"><h4>A. A. Adjei </h4></td><td width="1%" valign="top"><h4>8080</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34696.html">Efficacy
of erlotinib in patients (pts) with advanced non-small-cell lung cancer
(NSCLC) relative to clinical characteristics: Subset analyses from the
TRUST study.</a></td><td width="1%" valign="top"><h4>S. G. Allan </h4></td><td width="1%" valign="top"><h4>8081</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31429.html">Molecular markers distinguish patients at differential risk of brain metastases in lung cancer by immunohistochemistry.</a></td><td width="1%" valign="top"><h4>D. N. Hayes </h4></td><td width="1%" valign="top"><h4>8083</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31035.html">hase
II study of irinotecan and S-1 combination therapy in patients (pts)
with advanced non-small cell lung cancer (NSCLC): (WJTOG3505).</a></td><td width="1%" valign="top"><h4>O. Ishimoto </h4></td><td width="1%" valign="top"><h4>8084</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34884.html">Safety
of bevacizumab-based therapy as first-line treatment of patients with
advanced or recurrent non-squamous non-small cell lung cancer (NSCLC):
MO19390 (SAiL).</a></td><td width="1%" valign="top"><h4>E. Dansin </h4></td><td width="1%" valign="top"><h4>8085</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34317.html">Randomized
phase II trial of first-line gefitinib, gemcitabine or docetaxel in
performance status (PS) 2 or 3 non-small-cell lung cancer (NSCLC)
patients (IFCT-0301).</a></td><td width="1%" valign="top"><h4>J. Morere </h4></td><td width="1%" valign="top"><h4>8086</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32533.html">Should
3-weekly docetaxel (3WD) remain the standard for second-line therapy of
advanced non-small-cell lung cancer (A-NSCLC)? Meta-analysis of 7
randomized clinical trials (RCTs) with 3WD comparator arms.</a></td><td width="1%" valign="top"><h4>F. De Marinis </h4></td><td width="1%" valign="top"><h4>8087</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31707.html">Impact
of the Comprehensive Health Enhancement Support System (CHESS), an
interactive computer support system (ICSS) on non small cell lung
cancer (NSCLC) survival: A randomized study comparing CHESS with the
internet.</a></td><td width="1%" valign="top"><h4>J. F. Cleary </h4></td><td width="1%" valign="top"><h4>8088</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31079.html">Refining
epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR)
phenotypes with a cetuximab (C) monotherapy stage of a phase II trial
for non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>M. L. Maitland </h4></td><td width="1%" valign="top"><h4>8089</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33315.html">Chemotherapy
(C) and survival among 21,441 elderly (E) patients (pts) with advanced
(adv) NSCLC: Analysis of SEER-Medicare claim data 1997-2002.</a></td><td width="1%" valign="top"><h4>M. Tang </h4></td><td width="1%" valign="top"><h4>8090</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35167.html">Detection
of serum proteomic profile predictive for epidermal growth factor
receptor tyrosine kinase inihibitors (EGFR-TKIs) in 1st line
chemotherapy responders.</a></td><td width="1%" valign="top"><h4>C. Belli </h4></td><td width="1%" valign="top"><h4>8091</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34183.html">Randomized
phase II study of maintenance irinotecan therapy versus observation
following induction chemotherapy with irinotecan and cisplatin in
extensive disease small cell lung cancer (ED-SCLC).</a></td><td width="1%" valign="top"><h4>J. Han </h4></td><td width="1%" valign="top"><h4>8093</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35701.html">The actuarial incidence of brain metastases in 975 patients undergoing surgery for early-stage lung cancer.</a></td><td width="1%" valign="top"><h4>J. A. Boyd </h4></td><td width="1%" valign="top"><h4>8094</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35016.html">emetrexed
as second-line treatment for patients with advanced non-small cell lung
cancer (NSCLC): Efficacy and correlation with molecular markers.</a></td><td width="1%" valign="top"><h4>A. Blasco </h4></td><td width="1%" valign="top"><h4>8095</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34633.html">Comparison
of patient outcomes stratified by histology among pemetrexed
(P)-treated patients (pts) with stage IIIB/IV non-small cell lung
cancer (NSCLC) in two phase II trials.</a></td><td width="1%" valign="top"><h4>G. Peng </h4></td><td width="1%" valign="top"><h4>8096</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35169.html">Resource
utilization by non-small cell lung cancer histology: Results from the
randomized, phase III trial of pemetrexed/cisplatin versus
gemcitabine/cisplatin.</a></td><td width="1%" valign="top"><h4>F. L. Pimentel </h4></td><td width="1%" valign="top"><h4>8097</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31565.html">Genotyping
single-nucleotide polymorphisms (SNPs) in ERCC1 and XRCC3 genes for
efficacy prediction in chemotherapy of non-small cell lung cancer
(NSCLC).</a></td><td width="1%" valign="top"><h4>C. Zhou </h4></td><td width="1%" valign="top"><h4>8098</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33491.html">NGR-hTNF,
a novel vascular targeting agent (VTA), as second-line therapy in
malignant pleural mesothelioma (MPM): Preliminary results of
multicenter phase II study.</a></td><td width="1%" valign="top"><h4>V. Gregorc </h4></td><td width="1%" valign="top"><h4>8099</h4></td></tr></tbody></table>

jimmy112199

<table width="98%" cellspacing="0" cellpadding="3" border="0"><tbody><tr id="vmtablerowlight"><td width="1%" valign="top"><br/></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33928.html">hase
III multicenter web-based study demonstrating survival equivalents of
nonplatinum-based chemotherapy for advanced non-small cell lung cancer
(NSCLC): Subgroup analysis from D0112.</a></td><td width="1%" valign="top"><h4>J. R. Rigas </h4></td><td width="1%" valign="top"><h4>8100</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33020.html">Gefitinib combined survival analysis of the mutation positives from the prospective phase II trials (I-CAMP).</a></td><td width="1%" valign="top"><h4>S. Morita </h4></td><td width="1%" valign="top"><h4>8101</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33698.html">Influence of baseline inflammatory markers on the response to first line chemotherapy and overall survival in advanced NSCLC.</a></td><td width="1%" valign="top"><h4>G. Kasymjanova </h4></td><td width="1%" valign="top"><h4>8102</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32196.html">Randomized
phase II study of two different schedules of gemcitabine and oral TS-1
in chemo-na&#239;ve patients with advanced non-small cell lung cancer
(NSCLC).</a></td><td width="1%" valign="top"><h4>M. Satouchi </h4></td><td width="1%" valign="top"><h4>8103</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32152.html">hase
II trial of cetuximab (C225) in combination with monthly carboplatin
(Cb) and weekly paclitaxel (Pac) in patients with advanced NSCLC:
Promising early results.</a></td><td width="1%" valign="top"><h4>H. Borghaei </h4></td><td width="1%" valign="top"><h4>8104</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30374.html">Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib.</a></td><td width="1%" valign="top"><h4>D. B. Costa </h4></td><td width="1%" valign="top"><h4>8105</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34878.html">The
impact of zoledronic acid treatment on frequency of skeletal
complications experienced and on followup duration post diagnosis of
bone metastasis in lung cancer patients.</a></td><td width="1%" valign="top"><h4>H. T. Hatoum </h4></td><td width="1%" valign="top"><h4>8106</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35094.html">T790M mutation and c-MET amplification might be correlated to TTP of EGFR-TKI in NSCLC.</a></td><td width="1%" valign="top"><h4>Y. Wu </h4></td><td width="1%" valign="top"><h4>8107</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31272.html">A
phase II prospective study evaluating the role of pemetrexed plus
gemcitabine (Pem/Gem) chemotherapy as intial treatment in patients with
stage IIIB/IV non-small cell lung cancer (NSCLC) using a genomic
predictor of cisplatin-resistance to guide therapy.</a></td><td width="1%" valign="top"><h4>J. Garst </h4></td><td width="1%" valign="top"><h4>8108</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33697.html">reliminary cost-consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2^nd line therapy in advanced non-small cell lung cancer.</a></td><td width="1%" valign="top"><h4>A. M. Horgan </h4></td><td width="1%" valign="top"><h4>8110</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34834.html">A
phase II study of first-line erlotinib in patients (pts) with stage
IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to
toxicity in current and former smokers (C/FS).</a></td><td width="1%" valign="top"><h4>B. Besse </h4></td><td width="1%" valign="top"><h4>8111</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33001.html">Association
of tumoral BRCA1, RRM1 and RRM2 mRNA expression levels with clinical
responses to front-line docetaxel/gemcitabine (DG) chemotherapy in
patients with non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>C. Papadaki </h4></td><td width="1%" valign="top"><h4>8112</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30925.html">Risk of cerebral metastases for postoperative locally advanced non-small cell lung cancer.</a></td><td width="1%" valign="top"><h4>S. Wang </h4></td><td width="1%" valign="top"><h4>8113</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35210.html">Risk
of symptomatic central nervous system (CNS) progression and secondary
hemorrhage in patients with non-squamous non-small cell lung cancer
(NSCLC) receiving bevacizumab (BV)-based first-line therapy.</a></td><td width="1%" valign="top"><h4>V. Archer </h4></td><td width="1%" valign="top"><h4>8114</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34557.html">A
phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with
standard dose pemetrexed in previously treated advanced or metastatic
non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>. M. Ellis </h4></td><td width="1%" valign="top"><h4>8115</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32127.html">Imatinib for the treatment of thymic carcinoma.</a></td><td width="1%" valign="top"><h4>J. T. Salter </h4></td><td width="1%" valign="top"><h4>8116</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31885.html">Cetuximab
(C) and gemcitabine (G) in elderly or adult PS2 advanced non small-cell
lung cancer (NSCLC) patients (pts): The CALC1 randomised phase II
trials.</a></td><td width="1%" valign="top"><h4>C. Gridelli </h4></td><td width="1%" valign="top"><h4>8117</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32276.html">hase II trial of belotecan in patients with sensitive relapsed small-cell lung cancer after irinotecan-containing chemotherapy.</a></td><td width="1%" valign="top"><h4>J. Jeong </h4></td><td width="1%" valign="top"><h4>8118</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35025.html">The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>H. Groen </h4></td><td width="1%" valign="top"><h4>19000</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34939.html">Efficacy
and safety of erlotinib in &gt;1200 East/South-East (E/SE) Asian
patients (pts) with advanced non-small-cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>T. S. Mok </h4></td><td width="1%" valign="top"><h4>19001</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34575.html">Second-line erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): Results from a large, open-label study.</a></td><td width="1%" valign="top"><h4>L. Crinò </h4></td><td width="1%" valign="top"><h4>19002</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31990.html">Survival
benefits of zoledronic acid in patients with bone metastases from
non-small cell lung cancer and high NTX levels: The role of BALP.</a></td><td width="1%" valign="top"><h4>J. E. Brown </h4></td><td width="1%" valign="top"><h4>19003</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32051.html">hase
I/II study of AT-101 in combination with topotecan in patients with
relapsed or refractory small cell lung cancer after prior platinum
containing first line chemotherapy.</a></td><td width="1%" valign="top"><h4>R. S. Heist </h4></td><td width="1%" valign="top"><h4>19004</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33288.html">Feasibility
of cetuximab in combination with gemcitabine or docetaxel or
carboplatin/gemcitabine for chemona&#239;ve patients with advanced non-small
cell lung cancer (NSCLC): Observations from an ongoing randomized phase
II/III trial (GemTax IV).</a></td><td width="1%" valign="top"><h4>L. R. Pilz </h4></td><td width="1%" valign="top"><h4>19005</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31518.html">Final
results of randomized study of gemcitabine (G) plus cisplatin (P)
versus etoposide (E) plus cisplatin in locally advanced or metastatic
non small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>A. Bousahba Sr.</h4></td><td width="1%" valign="top"><h4>19006</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32838.html">lasma EGFR and Her2 levels in non-small cell lung cancer patients treated with gefitinib.</a></td><td width="1%" valign="top"><h4>K. Kasahara </h4></td><td width="1%" valign="top"><h4>19007</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32849.html">Monochemotherapy vs. doublet vs. triplet chemotherapy (CTX) with predefined sequence for 2^nd-line therapy in stage IIIb and IV NSCLC: A randomised phase III trial.</a></td><td width="1%" valign="top"><h4>T. H. Fink </h4></td><td width="1%" valign="top"><h4>19008</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32725.html">hase
II trial of 21-day regimen of irinotecan and carboplatin for chemonaive
or relapsed small-cell lung cancer: Long-term survival.</a></td><td width="1%" valign="top"><h4>G. Q. Chen </h4></td><td width="1%" valign="top"><h4>19009</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35570.html">redictive and prognostic biomarker models in advanced lung cancer.</a></td><td width="1%" valign="top"><h4>S. Holdenrieder </h4></td><td width="1%" valign="top"><h4>19010</h4></td></tr></tbody></table>

jimmy112199

<table width="98%" cellspacing="0" cellpadding="3" border="0"><tbody><tr id="vmtablerowdark"><td width="1%" valign="top"><br/></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33142.html">Use
of tumoral expression TXR1 and TSP1 to predict overall survival of
patients with non-small-cell-lung-cancer (NSCLC) treated with first
line chemotherapy.</a></td><td width="1%" valign="top"><h4>J. Souglakos </h4></td><td width="1%" valign="top"><h4>19011</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34446.html">Biomarker analyses from an open-label study of erlotinib in advanced non-small-cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>N. van Zandwijk </h4></td><td width="1%" valign="top"><h4>19012</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31994.html">aclitaxel
(P) plus bevacizumab (B) in patients (pts) with chemosensitive relapsed
small cell lung cancer (SCLC): A safety, feasibility and efficacy trial
from the Hoosier Oncology Group.</a></td><td width="1%" valign="top"><h4>S. I. Jalal </h4></td><td width="1%" valign="top"><h4>19013</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32200.html">hase
I-II study of irinotecan (CPT-11) and gefitinib in patients (pts) with
gefitinib failure for non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>A. Horiike </h4></td><td width="1%" valign="top"><h4>19014</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35150.html">Time
trend and risk factor for treatment-related death (TRD) in patients
with advanced non-small cell lung cancer (NSCLC) receiving systemic
chemotherapy in phase III trials.</a></td><td width="1%" valign="top"><h4>Y. Fujiwara </h4></td><td width="1%" valign="top"><h4>19015</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35309.html">Erlotinib as 1st-line therapy for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>O. Merimsky </h4></td><td width="1%" valign="top"><h4>19016</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30850.html">hase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC).</a></td><td width="1%" valign="top"><h4>T. K. Owonikoko </h4></td><td width="1%" valign="top"><h4>19017</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32137.html">A
phase II study of oxaliplatin and pemetrexed plus bevacizumab in
advanced non-squamous non-small cell lung cancer (An International
Oncology Network study, #I-04-015).</a></td><td width="1%" valign="top"><h4>J. M. Waples </h4></td><td width="1%" valign="top"><h4>19018</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32933.html">Oral
treatment with uracil-tegafur, etoposide and leucovorin in non-Asian
patients with recurrent non-small cell lung cancer: A non-randomized,
phase II study.</a></td><td width="1%" valign="top"><h4>V. F. Surmont </h4></td><td width="1%" valign="top"><h4>19019</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35469.html">Local therapy of primary disease and survival in non-small cell lung cancer metastatic to brain and other single organ sites.</a></td><td width="1%" valign="top"><h4>J. Lee </h4></td><td width="1%" valign="top"><h4>19020</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33933.html">Mutation detection in lung tumors: Comparing high-resolution melting with direct sequencing.</a></td><td width="1%" valign="top"><h4>E. H. Lim </h4></td><td width="1%" valign="top"><h4>19021</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32021.html">Improved survival in patients with malignant pleural mesothelioma since 2003.</a></td><td width="1%" valign="top"><h4>M. Serke </h4></td><td width="1%" valign="top"><h4>19022</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35811.html">hase
II trial of satraplatin (S) and paclitaxel (P) in first-line advanced
non-small cell lung cancer (NSCLC) treatment: Final results.</a></td><td width="1%" valign="top"><h4>D. S. Thompson </h4></td><td width="1%" valign="top"><h4>19023</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34390.html">Liposomally-encapsulated
cisplatin (Lipoplatin) plus gemcitabine in NSCLC: Preliminary results
of a phase II trial and its antiangiogenesis potential.</a></td><td width="1%" valign="top"><h4>T. Boulikas </h4></td><td width="1%" valign="top"><h4>19024</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31771.html">Osteopontin
and basic fibroblast growth factor are associated with prognosis in
advanced non-small cell lung cancer (JMTO LC 0004).</a></td><td width="1%" valign="top"><h4>T. Kawaguchi </h4></td><td width="1%" valign="top"><h4>19025</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32803.html">Circulating tumor cell analysis in patients with non-small cell lung cancer.</a></td><td width="1%" valign="top"><h4>T. Kato </h4></td><td width="1%" valign="top"><h4>19026</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33747.html">Epithelial-mesenchymal transition and brain metastasis in non-small cell lung cancer.</a></td><td width="1%" valign="top"><h4>B. W. Goodgame </h4></td><td width="1%" valign="top"><h4>19027</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33420.html">hase II trial of vinflunine (VFL) in sensitive and refractory relapsed small-cell lung cancer (SCLC): Updated results.</a></td><td width="1%" valign="top"><h4>S. D. Lunin </h4></td><td width="1%" valign="top"><h4>19028</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33997.html">Trends in metastatic sites and survival for patients (pts) with stage IV lung cancer.</a></td><td width="1%" valign="top"><h4>K. Kubota </h4></td><td width="1%" valign="top"><h4>19029</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33738.html">hase
I study of bortezomib plus cetuximab in patients with tumors expressing
epidermal growth factor receptor (EGFR)--Final report.</a></td><td width="1%" valign="top"><h4>O. N. Pandey </h4></td><td width="1%" valign="top"><h4>19030</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31251.html">hase
II randomized study of gefitinib alone or plus UFUR treatment in
Taiwanese patients with adenocarcinoma of the lung who failed at least
two regimens.</a></td><td width="1%" valign="top"><h4>Y. Chen </h4></td><td width="1%" valign="top"><h4>19031</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32439.html">Irinotecan and carboplatin for treatment of brain metastases from small-cell lung cancer.</a></td><td width="1%" valign="top"><h4>D. H. Lau </h4></td><td width="1%" valign="top"><h4>19032</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33484.html">A
phase II trial of single-agent vinflunine as second-line treatment for
advanced non-small cell lung cancer (An International Oncology Network
Study, #I-05-009).</a></td><td width="1%" valign="top"><h4>M. Joppert </h4></td><td width="1%" valign="top"><h4>19033</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35228.html">Changes
in serum proteomic profile of non-small cell lung cancer (NSCLC)
patients during therapy with epidermal growth factor receptor tirosine
kinase inhibitors (EGFR-TKIs): Preliminary report.</a></td><td width="1%" valign="top"><h4>A. Spreafico </h4></td><td width="1%" valign="top"><h4>19034</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34934.html">A
phase I trial of the small molecule pan-bcl-2 inhibitor obatoclax
(GX15-070) in combination with docetaxel in patients with relapsed
non-small cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>E. B. Haura </h4></td><td width="1%" valign="top"><h4>19035</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_31482.html">hase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>R. A. Juergens </h4></td><td width="1%" valign="top"><h4>19036</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_30276.html">rognostic
factors in previously treated non-small cell lung cancer patients with
and without a positive response to gefitinib treatment.</a></td><td width="1%" valign="top"><h4>Y. Ichinose </h4></td><td width="1%" valign="top"><h4>19037</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32850.html">emetrexed
(P) alone or in combination with platinum for malignant pleural
mesothelioma (MPM): Efficacy and toxicity of the International Expanded
Access Program (EAP) in Spanish patients (p).</a></td><td width="1%" valign="top"><h4>T. Moran </h4></td><td width="1%" valign="top"><h4>19038</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32860.html">Phase
II study of irinotecan plus cisplatin followed by amrubicin in patients
with extensive-stage small-cell lung cancer (WJTOG 0301).</a></td><td width="1%" valign="top"><h4>Y. Iwamoto </h4></td><td width="1%" valign="top"><h4>19039</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34440.html">Current
trends in prophylactic cranial irradiation (PCI) for extensive-disease
small cell lung cancer (EDSCLC): Results of a UK survey.</a></td><td width="1%" valign="top"><h4>N. Bayman </h4></td><td width="1%" valign="top"><h4>19040</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_35489.html">Prognostic
importance of performance status (PS) in small cell lung cancer (SCLC):
A North Central Cancer Treatment Group (NCCTG) investigation.</a></td><td width="1%" valign="top"><h4>N. R. Foster </h4></td><td width="1%" valign="top"><h4>19041</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32663.html">Value
of CYFRA 21-1,carcinoembryonic antigen, and squamous cell carcinoma
antigen as tumor markers in non-small cell lung cancer patients.</a></td><td width="1%" valign="top"><h4>J. L. Patel </h4></td><td width="1%" valign="top"><h4>19042</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_33434.html">Phase
II study of sabarubicin (MEN 10755) in newly diagnosed patients with
extensive stage small cell lung cancer (ESCLC): Final report.</a></td><td width="1%" valign="top"><h4>K. J. O'Byrne </h4></td><td width="1%" valign="top"><h4>19043</h4></td></tr><tr id="vmtablerowdark"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_32286.html">Elevated
pretreatment serum concentration of YKL-40--An independent prognostic
biomarker for poor survival in patients with metastatic non-small cell
lung cancer.</a></td><td width="1%" valign="top"><h4>I. Thoem </h4></td><td width="1%" valign="top"><h4>19044</h4></td></tr><tr id="vmtablerowlight"><td width="99%" valign="top" id="h4indent" class="vmindenttable"><a href="http://www.abstract.asco.org/AbstView_55_34583.html">Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC).</a></td><td width="1%" valign="top"><h4>J. R. Rubinsak </h4></td><td width="1%" valign="top"><h4>19045</h4></td></tr></tbody></table>